Survey of Ophthalmology
Volume 53, Issue 2 , Pages 150-163, March 2008

The Role of Calcium-Activated Protease Calpain in Experimental Retinal Pathology

  • M. Azuma, PhD

      Affiliations

    • Department of Integrative Biosciences, Oregon Health & Science University, Portland, Oregon, USA
    • Senju Laboratory of Ocular Sciences, Senju Pharmaceutical Co., Ltd., OHSU West Campus, Beaverton, Oregon, USA
  • ,
  • T.R. Shearer, PhD

      Affiliations

    • Department of Integrative Biosciences, Oregon Health & Science University, Portland, Oregon, USA
    • Corresponding Author InformationReprint address: Dr. T.R. Shearer, Department of Integrative Biosciences, Oregon Health and Science University, 611 Southwest Campus Drive, Portland, OR 97239-3097, USA.

Edward Cotlier and Robert Weinreb, Editors

Abstract 

The purpose of this review is to present the recent evidence linking the family of ubiquitous proteases called calpains (EC 3.4.22.17) to neuropathologies of the retina. The hypothesis being tested in such studies is that over-activation of calpains by elevated intracellular calcium contributes to retinal cell death produced by conditions such as elevated intraocular pressure and hypoxia. Recent x-ray diffraction studies have provided insight into the molecular events causing calpain activation. Further, x-ray diffraction data has provided details on how side chains on calpain inhibitors affect docking into the active site of calpain 1. This opens the possibility of testing calpain-specific inhibitors, such as SJA6017 and SNJ1945, for human safety and as a site-directed form of treatment for retinal pathologies.

Key words: calpain, calpain activation, calpain inhibitors, glaucoma models, human disease, molecular genetics, molecular modeling, neurochemistry, neuropathology, retina, retinitis pigmentosa models, x-ray diffraction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Partially funded by NIH grant No. EY05786. Dr. Shearer is a paid consultant for Senju Pharmaceutical Co., Ltd., a company that may have a commercial interest in the results of this research and technology. Dr. Azuma is an employee of Senju Pharmaceutical Co., Ltd. These potential conflicts of interest have been reviewed and managed by the OHSU. We thank Marjorie Shih and Dr. Larry David at OHSU for help in with mass spectroscopy, and Dr. Hong Ma for the pictures in Fig. 1.

PII: S0039-6257(07)00305-0

doi:10.1016/j.survophthal.2007.12.006

Refers to erratum:

Survey of Ophthalmology
Volume 53, Issue 2 , Pages 150-163, March 2008